✦ LIBER ✦
24 A cost-effectiveness analysis on the use of erlotinib (Tarceva) in the maintenance treatment of locally advanced or metastatic NSCLC patients with stable disease (SD) as best response to induction
✍ Scribed by McNamara, S.; Nuijten, M.; Summerhayes, M.; Ray, J.; Walzer, S.
- Book ID
- 118574697
- Publisher
- Elsevier Science
- Year
- 2011
- Tongue
- English
- Weight
- 35 KB
- Volume
- 71
- Category
- Article
- ISSN
- 0169-5002
No coin nor oath required. For personal study only.